We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rescue Rates for Talimogene laherparepvec Use in Loco-Regionally Progressing Cutaneous Melanoma Refractory to PD1 Inhibition.
- Authors
Roberts, Morgan E.; Vines, Katie; Sullivan, Frances G.; Phung, Thuy; Liles, Joe S.; Howard, John H.
- Abstract
A study published in the American Surgeon journal explores the use of Talimogene laherparepvec (T-VEC) as a treatment for cutaneous melanoma that has progressed despite PD1 inhibition. T-VEC is an FDA-approved oncolytic virus that is administered directly into metastatic lesions. The study found that 86% of patients responded to T-VEC treatment, with 66% achieving a complete pathologic response. The treatment was well-tolerated and had a low risk of adverse events. The results suggest that T-VEC may be an effective option for patients who have failed systemic immunotherapy.
- Subjects
IPILIMUMAB; PATHOLOGIC complete response; CLINICAL trials; TYPE 1 diabetes; MELANOMA
- Publication
American Surgeon, 2024, Vol 90, Issue 6, p1809
- ISSN
0003-1348
- Publication type
Article
- DOI
10.1177/00031348241241648